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Abstract Migraine is a complex
disorder caused by a combination
of genetic and environmental fac-
tors.
Although family and twin studies
show that there is a genetic com-
ponent in migraine, no genes pre-
disposing to common forms of the
disorder, migraine with and with-
out aura, have been identified.
Patients with migraine respond dif-
ferently to a given drug adminis-
tered. The efficacy of therapy and
the occurrence of adverse drug
response are a consequence of
individual variability. Genetic pro-
filing of predisposition to migraine
should facilitate the development
of more effective diagnostic and
therapeutic applications. The
development of International Hap
Map project could provide a pow-
erful tool for identification of the
candidate genes in this complex
disease and pharmacogenomics
research could be the promise for
individualized treatments and pre-
vention of adverse drug response. 
Keywords Pharmacogenomics •
Pharmacogenetics • Non-responder
patients • Migraine
Received: 1 September 2007
Accepted in revised form: 20 November 2007
Published online: 17 December 2007
©2007 The Author
1
M. Piane () • P. Lulli
Department of Diagnostic Sciences,
Medical Genetics Section,
2
nd School of Medicine,University 
of Rome La Sapienza, I-00185, Rome, Italy
e-mail: maria.piane@uniroma1.it
Tel.: +39-06-3377-5262
Fax: +39-06-3377-5422
I. Farinelli • S. De Filippis • P. Martelletti
Department of Medical Sciences, 
2
nd School of Medicine, University of Rome
La Sapienza, Internal Medicine, 
Regional Referral Headache Centre,
Sant'Andrea Hospital, Rome, Italy
S. Simeoni • F. R. Patacchioli
Department of Human Physiology and
Pharmacology, 2
nd School of Medicine,
Sapienza University of Rome, Rome, Italy
Introduction
Migraine is a complex disorder caused by a combination of
genetic and environmental factors. At present, the measure in
which these two factors influence each other is unknown. It is
possible to define this disease as a complex spectrum includ-
ing features such as craniofacial pain, autonomic dysfunctions,
mood disregulations and spreading cortical disturbance repre-
sented by both positive and negative aura phenomena [1–5].
Migraine diagnosis is based on anamnesis, a record
patient’s symptomatology and the exclusion of secondary
causes. A positive familial history often represents further
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familial aggregation appears in the calculation of disease rel-
ative risk of the population in specified groups of relatives.
Epidemiological surveys found that first-degree relatives of
probands displayed a much increased risk of developing the
disorder of proband as compared to the general population
[5]. The risk increase in close relatives obviously does not
imply the pathology’s manifestation but only the sharing of a
genotypic pattern, which determines the outbreak of clinical
manifestations after environmental stimuli of different kinds
(stress factors, food, smells).
At present, the International Headache Society (IHS) clas-
sification recognises some phenotypical features attributing
them to diagnostic subtypes. However, patients with the same
diagnosis present a symptomatological pattern (type of pain,
pain location, accompanying symptoms) underlining a great
variability of expressions. According to this view, migraine
could represent a syndrome whose clinical components are
the reflection of specific loci expressions, independently
influencing susceptibility to migraine [6].
The family aggregation of migraine with aura (MA) and
migraine without aura (MO) evidence that there is a genetic
component as the basis of migraine susceptibility. In a Finnish
study involving 2690 monozygotic and 5497 dizygotic twin
pairs, the genetic component ranged from 34% to 51% in dif-
ferent migraine types, without remarkable variations with
respect to gender.Such a concordance emphasises the multifac-
torial nature of this pathology [7]. Similar results have been
obtained in several studies on adult twin pairs [8–10].
Although family and twin studies show that there is a
genetic component in migraine, no genes predisposing to
common forms of the disorder have been identified. At pre-
sent, several loci 4q21-q24, 5q21, 6p12.2-p21.1, 11q24,
14q21.2-q22.3 and 15q11-q13 linked to common forms of
migraine with evidence of linkage have been reported.
Several genes were described involved in migraine in many
studies, but always with controversial results. In a more gen-
eral scenario, genetic studies on primary headaches constitute
challenges made more complex by this pathology.
Patients with migraine and headache respond differently
to a given drug administered. The efficacy of a drug therapy
and the occurrence of adverse reactions are a direct conse-
quence of individual variability. Most of this variation in indi-
vidual response is genetically determined and is the object of
the study of pharmacogenetics.
Familial hemiplegic migraine, a Mendelian model for
migraine
At present, the best genetic evidence providing molecular
insight into migraine comes from the mutations that have been
detected in a rare Mendelian form of migraine, named famil-
ial hemiplegic migraine (FHM) [11]. This represents the only
gene-related headache disorder that has been identified so far.
FHM is a rare subtype of MAwith an autosomal dominant
inheritance pattern; it is a primary headache form charac-
terised by motor weakness (transient hemiparesis or hemiple-
gia) during the aura phase of migraine attacks, and similar
episodes in at least one first- or second-degree family mem-
ber. Migraine symptoms are similar to those of “normal”
migraine patients. FHM is genetically heterogeneous.
Mutations in three different genes have been identified in
FHM families: CACNA1A gene, involved in FHM type 1
(FHM1), localised to chromosome 19p13, encoding for the
α1A subunit of the neuronal voltage-gated calcium channel
Cav2.1 (neuronal P/Q-type calcium channel) [12]; ATP1A2
gene localised to chromosome 1q21-23, implicated in FHM
type 2 (FHM2) encoding for the α2 subunit of the Na
+,K
+-
ATPase isoform [13]; and SCN1A gene localised to chromo-
some 2q24, implicated in FHM type 3 (FHM3), encoding a
neuronal voltage-gated sodium channel (Nav1.1) [14]. All of
them are expressed at cerebral level. Patients affected by
FHM present a symptomatic range of which migraine consti-
tutes just one aspect. In fact, some FHM families can present
with only cerebellar degeneration or seizures and in the same
way several genes, isolated in FHM families, are also
involved in other neurological disorders with an autosomal
dominant inheritance pattern such as episodic ataxia type 2
and spinocerebellar ataxia type 6 [15, 16].
Functional studies of FHM support the hypothesis that ion
transport dysfunction is one of the main factors determining
susceptibility of the brain to migraine attacks. New therapeu-
tic strategies are aimed at controlling cortical hyperexcitabil-
ity to prevent clinical manifestations: the protracted adminis-
tration of some anti-migraine drugs would appear to change
the expression of the genes.
Thus, the genes involved in FHM pathogenesis could be
possible therapeutic targets, although the many studies inves-
tigating the role of CACNA1A gene in common forms of
migraine have produced contradictory results [17, 18].
More generally, the role of FHM genes codifying for neu-
ronal channels as Cav2.1, Nav1, Na
+ and K
+-ATPase at the
cerebral level constitute a possible object of pharmacogenom-
ic research [19].
This is true for FHM, but it seems to be far from a com-
mon form of migraine.
Candidate genes and polymorphisms involved in migraine
Although the three FHM genes represent the main candidate
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genes for understanding migraine pathogenesis also in the
more common forms, several case-control association studies
have indicated additional susceptibility genes implicated in
migraine with and without aura [20–27]. Most of the genes
identified to be associated to migraine need to be confirmed
by further studies, because of the heterogeneity of the sample
in terms of diagnosis, ethnic background and sample size,
before being able to consider them as predisposing genes.
The C677T polymorphism of the methylenetetrahydrofo-
late reductase (MTHFR) gene has been suggested to be asso-
ciated with MA in several populations [28], although recent-
ly in a large cohort of patients and controls this association
failed to be verified. Nevertheless the same study does not
confirm the positive association of the variants of ESR1
(oestrogen receptor α gene) with the migraine precedent
described [20, 29].
McCarthy et al. [22] identified five single-nucleotide
polymorphisms (SNPs) within the insulin receptor gene that
showed a significant association with migraine, suggesting
possible functions for the insulin receptor in the pathogenesis
of this disease. The association between common migraine
forms and the HLA system today represents one of the most
investigated aspects.
In a group of Italian migraine patients, Martelletti et al.
[23] showed that the frequency of HLA DR2 antigen
decreased in the MAgroup when compared with both the MO
and the control group. These results seemed to support the
hypothesis of a protective role of DR2 antigen in MAand pro-
vided an additional basis for the proposed differences within
MO and MA.
In a subsequent study conducted in a larger cohort of
Italian patients, the associations of HLA DRB1 alleles and
migraine were reported [24]. The frequency of the HLA
DRB1*12 allele was found to be decreased in patients with
migraine while the DRB1*16 allele, coding for HLA DR2
antigen, was significantly increased in comparison with con-
trols. However once patients were divided into subgroups,
MO patients presented a significant increase of the HLA-
DRB*16 allele.
The discrepancy observed about DRB1*12 frequency in
these studies can be due to the different sizes of the two sam-
ples, but both studies observed that the frequency of HLA
DR2 was different between MAand MO groups, emphasising
that there is a different genetic background in the two sub-
types of migraine. A possible explanation for the association
of HLA DRB1 alleles with migraine lies in the fact that this
locus may be involved in susceptibility or may be in linkage
disequilibrium with other genes, because the DRB1 gene is
located on chromosome 6p21, within the HLAclass II region.
Recently, a significant association has been found
between migraine and the polymorphisms of two genes:
tumour necrosis factor-α (TNFA) and lymphotoxin α (TNFB),
localised in the HLA class III region. TNF-α is a proinflam-
matory cytokine involved in both the outset and regulation of
inflammatory response. The association of the TNFA308G/A
polymorphism with the occurrence of migraine has been
shown only in MO patients; patients homozygous for the G
allele present a higher risk of developing the disease. This
suggests that the TNFA gene or a locus in linkage disequilib-
rium may be implicated in the risk of disorder modulation
[25].
TNFB codifies for a cytokine involved in the formation of
secondary lymphoid organs during development and playing
a role in apoptosis. The Nco1 polymorphism in the first intron
of the TNFB gene (TNFB*1 and TNFB*2 alleles) in migraine
has been investigated. The frequency of the TFNB*2 allele is
significantly higher in MO patients, as compared with the
control group, but no significant differences have been found
between MA patients and controls. This evidence suggests a
possible role of lymphotoxin α in the genetic background of
migraine [26].
Given the possible role played by TNF genes and HLA,
the task of the cytotoxic T lymphocyte antigen 4 (CTLA-4)
has also been explored as they are negative regulators of T-
cell proliferation and therefore of cytokine production.
Nevertheless, the results of the survey on CTLA-4 polymor-
phism 49 A/G intron 1 failed to identify any positive associa-
tion in MO and MA patients [27].
Genetic bases of CDH and MOH
Another aspect that has been investigated is the relationship
between genetic factors and the possibility of developing
chronic forms of headache (chronic daily headache, CDH).
In MApatients, Peroutka et al. [30] explored the NcoI C/T
polymorphism (His313His) in exon 6 of the dopamine recep-
tor 2 gene (DRD2), located on chromosome 11q22. The
patients with the DRD2 NcoI C/C genotype presented a high-
er incidence of MA episodes, major depression and anxiety
disorders in comparison with individuals with a T allele.
Paterna et al. [31] showed an increase in the frequency of
migraine attacks in patients with angiotensin-converting
enzyme (ACE) allele D polymorphisms localised in 17q23.
CDH patients are predisposed to developing drug abuse
(medication overuse headache, MOH) [32]. Several studies
analysed this specific aspect in relation to genetic patterns. In
these patients a role of the dopamine metabolism-related gene
has been hypothesised. Polymorphisms of the dopamine
transporter (DAT) gene, which encodes a protein responsible
for presynaptic uptake of dopamine, are involved in the
development of drug abuse. Polymorphisms of the dopamine
receptor 4 (DRD4) gene are implicated in the predisposition337
to episodic migraine attacks but not in drug abuse [33].
The Wolfram gene (WFS1) is located on chromosome
4p16.1 and codifies for Wolframin, a transmembrane protein
expressed in all cell types, in the brain predominantly in the
limbic system or in structures closely related to it. Mutations
in this gene are associated to Wolfram syndrome, a neurode-
generative disorder related to diabetes mellitus, diabetes
insipidus, hearing loss, progressive blindness and a heteroge-
neous combination of psychiatric disorders. Thus, in MOH
patients that show both an increase in abuse of symptomatic
drugs and major psychiatric disorders, the His611Arg poly-
morphism of the WFS1 gene has been investigated.
Individuals harbouring the R/R (arg/arg) genotype showed
significantly higher monthly drug consumption and more
severe depressive symptoms than non-R/R individuals. This
genetic substrate could constitute a possible marker of prog-
nostic differentiation in MOH patients [34].
Pharmacogenomics in migraine
Patients with migraine and headache respond differently to
given drugs. The efficacy of a drug therapy and the occur-
rence of adverse reactions are a direct consequence of indi-
vidual variability, which is a complex trait depending on both
genetic background (the genetic component present in each of
us) and environmental factors [35, 36]. Most of this variation
in individual response is genetically determined and is the
object of the study of pharmacogenetics. Genetic factors
influence the pharmacokinetics (absorption, distribution,
metabolism and excretion of the drug) and pharmacodynam-
ics (drug effect); the genetic variability determines the differ-
ent ways in which a drug exerts its effect, for example by
influencing the link with the target of the drug on which it
acts; moreover it could make receptors, enzymes and pro-
teins, involved in metabolism of a drug, different in structure
and function.
Pharmacogenomics deals with the DNA and RNA varia-
tions related to a drug response; the gene expression study can
be used as a diagnostic tool to predict whether a patient will
respond to a drug well or badly, or not at all [37–39]. The real-
istic promises of migraine pharmacogenomic-based therapies
are the advent of “individually-tailored drugs” and the poten-
tial to reduce costs not only in terms of money but also in
human suffering and lost productivity [40]. Nowadays a great
deal of scientific literature regarding genetic studies applied
to migraine treatment can be found [41–44].
Pharmacogenetic information might be applied for identi-
fication of cases where certain drugs are simply not effective.
In fact, pharmacogenomic factors can modify the drug
response of an organism through a pharmacokinetic and phar-
macodynamic action. The enzymes that metabolise drugs
could present polymorphisms able to profoundly influence
the dose–response relation among different patients.
Knowledge of these polymorphisms is necessary for many
drugs before starting a therapy.
Genetic profiling of predisposition to migraine should
facilitate the development of more effective diagnostic and
therapeutic applications.
Possible targets of pharmacogenomic research are both
the serotoninergic and dopaminergic systems [38, 45]. The
role of the serotoninergic system is suggested by the use of
triptans in acute treatment. Triptans are drugs that act selec-
tively as agonists on 5-HT1B/1D receptors producing vaso-
constriction of meningial vessels as well as direct action on
central pathways of trigeminal transmission [46, 47]. In sev-
eral studies the relationship between polymorphisms of 5-
HT1B receptors and clinical response to sumatriptan has been
investigated, however without being able to establish an
unquestionable link between them [48]. The serotoninergic
system’s role is also suggested by the use of antidepressants,
such as selective serotonin reuptake inhibitor (SSRI), in pro-
phylaxis treatment [49].
Several studies indicate that hypersensitivity of the
dopaminergic system is implicated in the pathogenesis of
migraine [50]. In fact, as reported above, an association
between DRD2 gene and MAhas been demonstrated [44, 51].
Moreover, some accompanying symptoms of migraine are
mediated by the dopaminergic system (nausea, vomiting),
underlining a possible role in clinical susceptibility to
migraine.
Adverse drug response and pharmacogenomics
In terms of drug efficacy and toxicity, individual variability is
associated with genetic variations in absorption and distribu-
tion into the site of action, or more generally in drug metabo-
lism. In the same way the field can be extended to genes
encoding drug transporters, drug receptors and other drug tar-
gets.
However, the majority of genetic factors involved in the
variability of therapeutic effects and/or adverse drug response
(ADR) are unknown and so far no molecular genetic clues
have been identified for the more common types of primary
headaches.
In recent years it has become clear that genetic factors
could greatly modify drug responses as well as increase the
risk of occurrence of ADR. In a review that analysed studies
carried out between 1995 and 2000, the association between
ADR of some drugs and the presence of at least one enzyme
with a variant allele known to cause poor metabolism has338
been evidenced. These results suggest that a therapy based on
genetic information could turn out to be clinically effective in
the reduction of adverse outcomes [52].
If genetic information such as the allelic variants of
enzymes involved in the metabolism was known, the choice
of a therapy could be effectuated more precisely. However,
the complex metabolic pathways of several drugs must be
taken into account.
Conclusions
At the moment it is difficult to identify the best model for
pharmacogenomics studies. Linkage studies failed to identi-
fy a valid model for the study of common forms of migraine.
Until now, only one or few SNPs have been analysed in
most studies of genetic association in migraine. This
approach has often led to conflicting results, as a conse-
quence of using both different protocols and heterogeneous
samples regarding ethnicity and size. The development of
the International HapMap project [53] could also provide a
powerful tool for identification of candidate genes in this
complex disease [54]. Most chromosomes carry one of a
few common ancestral haplotypes. These haplotypes in
which SNPs are grouped in linkage disequilibrium blocks
(tag SNP), identified by the HapMap project, can be used
for the association study of genes as candidates for the pres-
ence of common variants that confer susceptibility to the
disease. If a genetic variant on an ancestral chromosome
increases risk of disease, the related ancestral haplotype
will also be associated to the disease. So, tag SNP can be
used as markers to identify the location of the disease vari-
ant, reducing genotyping costs and moreover standardising
study design.
In the future, in addition to targeting a patient's drug con-
centrations within a therapeutic range, pharmacists are like-
ly to be making dosage recommendations for individual
drugs on the basis of the individual patient's genotype. As
we enter the era of personalised drug therapy, we will be
able to identify not only the best drug to be administered to
a particular patient, but also the most effective and safest
dosage from the outset of therapy.
Other advantages of genotyping over traditional thera-
peutic drug monitoring include the discovery of new targets
for migraine therapy. Identification of polymorphisms and
genetic biomarkers should help us to better understand
migraine pathology and therefore choose the most effective
treatments for migraine patients.
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